scholarly journals Nonpharmacological Versus Pharmacological Treatments for Adult Patients With Major Depressive Disorder

2016 ◽  
Vol 14 (2) ◽  
pp. 283-293
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Adult Patients ◽  
Pharmacological Treatments ◽  
Major Depressive

scholarly journals Childhood Adversity Impairs Theory of Mind Abilities in Adult Patients With Major Depressive Disorder

2019 ◽  
Vol 10 ◽  
Author(s):  
Maria Simon ◽  
Nándor Németh ◽  
Mónika Gálber ◽  
Elza Lakner ◽  
Eszter Csernela ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Theory Of Mind ◽  
Depressive Disorder ◽  
Childhood Adversity ◽  
Adult Patients ◽  
Major Depressive

scholarly journals Blues in the Brain and Beyond: Molecular Bases of Major Depressive Disorder and Relative Pharmacological and Non-Pharmacological Treatments

Genes ◽  
2020 ◽  
Vol 11 (9) ◽  
pp. 1089 ◽  
Author(s):  
Elisabetta Maffioletti ◽  
Alessandra Minelli ◽  
Daniela Tardito ◽  
Massimo Gennarelli
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Molecular Mechanisms ◽  
Pharmacological Treatments ◽  
Major Depressive ◽  
Reciprocal Interactions ◽  
Evidence Based Treatments ◽  
Molecular Effects ◽  
Molecular Bases ◽  
The Brain

Despite the extensive research conducted in recent decades, the molecular mechanisms underlying major depressive disorder (MDD) and relative evidence-based treatments remain unclear. Various hypotheses have been successively proposed, involving different biological systems. This narrative review aims to critically illustrate the main pathogenic hypotheses of MDD, ranging from the historical ones based on the monoaminergic and neurotrophic theories, through the subsequent neurodevelopmental, glutamatergic, GABAergic, inflammatory/immune and endocrine explanations, until the most recent evidence postulating a role for fatty acids and the gut microbiota. Moreover, the molecular effects of established both pharmacological and non-pharmacological approaches for MDD are also reviewed. Overall, the existing literature indicates that the molecular mechanisms described in the context of these different hypotheses, rather than representing alternative ones to each other, are likely to contribute together, often with reciprocal interactions, to the development of MDD and to the effectiveness of treatments, and points at the need for further research efforts in this field.

scholarly journals Major depressive disorder is associated with subsequent adult-onset asthma: a population-based cohort study

2016 ◽  
Vol 26 (6) ◽  
pp. 664-671 ◽  
Author(s):  
T-C. Shen ◽  
C-L. Lin ◽  
C.H. Liao ◽  
C-C. Wei ◽  
F-C. Sung ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Proportional Hazards ◽  
Population Based ◽  
Cox Proportional Hazards ◽  
Adult Patients ◽  
Major Depressive ◽  
Significant Difference ◽  
Receptor Blockers

Aim.To examine the incidence of asthma in adult patients with major depressive disorder (MDD).Methods.From the National Health Insurance database of Taiwan, we identified 30 169 adult patients who were newly diagnosed with MDD between 2000 and 2010. Individuals without depression were randomly selected four times and frequency matched for sex, age and year of diagnosis. Both cohorts were followed-up for the occurrence of asthma up to the end of 2011. Adjusted hazard ratios (aHRs) of asthma were estimated using the Cox proportional hazards method.Results.The overall incidence of asthma was 1.91-fold higher in the MDD cohort than in the non-depression cohort (7.55 v. 3.96 per 1000 person-years), with an aHR of 1.66 (95% confidence interval (CI) 1.55–1.78). In both cohorts, the incidence of asthma was higher in patients and controls who were female, aged, with comorbidities and users of aspirin or beta-adrenergic receptor blockers. No significant difference was observed in the occurrence of asthma between patients with MDD treated with selective serotonin reuptake inhibitors (SSRIs) and those treated with non-SSRIs (SSRIs to non-SSRIs aHR = 1.03, 95% CI 0.91–1.17).Conclusion.Adult patients with MDD are at a higher risk of asthma than those without depression are.

Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder

2018 ◽  
Vol 33 (1) ◽  
pp. e2646
Author(s):  
Sidney H. Kennedy ◽  
Jean-Marie Grouin ◽  
Stéphanie Cadour ◽  
Véronique Robert ◽  
Françoise Picarel-Blanchot
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Adult Patients ◽  
Short Term ◽  
Major Depressive ◽  
Term Efficacy
Sign in / Sign up

Export Citation Format

Share Document